Helping You to Find Mechanistic Keys to Biomarker Discovery for Precision Oncology
View video
Kinase inhibitor profiling and resistance mechanisms presented at the AACR Annual Meeting 2021
April 8, 2021: NTRC will present two scientific posters at [...]
TDO is a novel therapeutic target for Parkinson’s disease
February 22, 2021: A new article on the pharmacological validation [...]
- Case study – Pharmacological models to assess the role of tryptophan-metabolizing enzymes in cancerNTRC Oncolines2021-02-12T10:20:52+01:00
- Case study – Synergistic interaction of olaparib and cisplatinNTRC Oncolines2021-02-11T17:59:29+01:00
PREMIUM BENEFITS OF NTRC PRECISION ONCOLOGY: Cell-Based Assays, Drug Combinations, High-Throughput Screening
Integration of cancer biology and big data analysis
Identification of patient selection markers
Side-by-side comparison with known anti-cancer agents
Discovery of targeted and novel synergistic drug combinations
Science-driven technology platforms
Short turnaround times
